10 Tips for Publishing in ACS Journals

Craig W. Lindsley, Ph.D. is the Director of the Warren Center for Neuroscience Drug Discovery (WCNDD) and University Distinguished Professor of Pharmacology, Chemistry & Biochemistry. Dr. Lindsley’s research is focused on the development of novel treatment strategies for schizophrenia, Alzheimer’s disease, Parkinson’s disease, Fragile X Syndrome and other brain disorders. In addition, his academic lab is focused on teaching the basic tenants of organic chemistry (synthetic methods, total synthesis, chemical biology) and then apply these skills to translational science problems. In 2009 Craig became the founding Editor-in-Chief of ACS Chemical Neuroscience, the interim EIC of ACS Pharmacology & Translational Science (2020) and the EIC of Journal of Medicinal Chemistry (2021- ). Recipient of major awards from ACS and ASPET, including induction into the ACS MEDI Hall of Fame (2021), and named a Fellow of the American Society for Pharmacology and Experimental Therapeutics, the Royal Society for Chemistry, the National Academy of Inventors and the American Association for the Advancement of Science.

Kelly Chibale is a professor of organic chemistry at the University of Cape Town (UCT) where he holds the Neville Isdell Chair in African-centric Drug Discovery & Development. He is also a member of the UCT Institute of infectious disease & molecular medicine, founding Director of the South African medical research council drug discovery & development research unit at UCT and the Founder and Director of the UCT drug discovery and development centre, H3D, a Johnson and Johnson (J&J) Satellite Centre for Global Health Discovery. His research interest is in infectious disease drug discovery. Kelly obtained his PhD in Synthetic Organic Chemistry from the University of Cambridge in the UK. This was followed by postdoctoral stints at the University of Liverpool in the UK and at the Scripps Research Institute in the USA. He was a Sandler Sabbatical Fellow at the University of California San Francisco, a US Fulbright Senior Research Scholar at the University of Pennsylvania School of Medicine, and a Visiting Professor at Pfizer. He is a recipient of many awards and honors, including being named by Fortune magazine as one of the World’s 50 Greatest Leaders in 2018. He previously served as an Associate Editor of Journal of Medicinal Chemistry.  

Dr. Lori Ferrins is a Research Associate Professor at Northeastern University. Her research focuses on the development of drugs for intractable diseases, including parasitic neglected tropical diseases, pathogenic free-living amoebae, and antifungal agents. Her research uses advanced models of infection to improve the translation of in vitro activity to in vivo efficacy, while also relying on the tenants of phenotypic and target driven optimization. Dr. Ferrins is also a Topic Editor for the Journal of Medicinal Chemistry and is passionate about promoting early career chemists.